Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis

被引:44
作者
Chen, WX [1 ]
KuoLee, R [1 ]
Shen, H [1 ]
Bùsa, M [1 ]
Conlan, JW [1 ]
机构
[1] Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada
关键词
Francisella tularensis; toll-like receptor 4; virulent; pathogenesis; mouse model;
D O I
10.1016/j.micpath.2004.06.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Francisella tularensis, the causative agent of tularemia, is a gram-negative facultative intracellular bacterium. Toll-like receptor (TLR) 4 is considered to be critical for inducing host innate immunity against many gram-negative bacteria including many respiratory pathogens. To determine the role of TLR4 in host defense against airborne F. tularensis infection, TLR4-defective C3H/HeJ (TLR4(d)) or wild-type C3H/HeOuJ (WT) mice were challenged by low-dose aerosol with type A F. tularensis, and the course of the infection and host responses were compared at day 2 and 4 post-inoculation (dpi). At dpi 2, bacterial burdens in the lungs were similar between TLR4(d) and WT mice, but TLR4(d) mice surprisingly harbored approximately 10-fold fewer bacteria in their spleens and livers. However, the bacterial burdens at dpi 4, the mortality and median time to irreversible moribundity were indistinguishable between the two mouse strains. In addition, the inflammatory responses to the infection, as reflected by the cytokine levels and leukocyte influx in the bronchoalveolar lavage fluid and histopathological analysis, were similar between both mouse strains. Additionally, as with C3H mice, we found no difference in either the median time to death or the survival rate between TLR4-deleted C57BL/10ScNJ mice and WT C57BL/10 mice. Combined, these data suggest that TLR4 does not contribute to resistance of mice to airborne type A F. tularensis infection. Crown Copyright (C) 2004 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 38 条
  • [1] Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins
    Ancuta, P
    Pedron, T
    Girard, R
    Sandstrom, G
    Chaby, R
    [J]. INFECTION AND IMMUNITY, 1996, 64 (06) : 2041 - 2046
  • [2] Role of toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice
    Branger, J
    Knapp, S
    Weijer, S
    Leemans, JC
    Pater, JM
    Speelman, P
    Florquin, SR
    van der Poll, T
    [J]. INFECTION AND IMMUNITY, 2004, 72 (02) : 788 - 794
  • [3] Chapes SK, 2001, J LEUKOCYTE BIOL, V69, P381
  • [4] CHEN WX, 1992, INT J EXP PATHOL, V73, P709
  • [5] INTERLEUKIN-1 - AN IMPORTANT MEDIATOR OF HOST-RESISTANCE AGAINST PNEUMOCYTIS-CARINII
    CHEN, WX
    HAVELL, EA
    MOLDAWER, LL
    MCINTYRE, KW
    CHIZZONITE, RA
    HARMSEN, AG
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (03) : 713 - 718
  • [6] Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis:: bacteriologic and histopathologic studies
    Conlan, JW
    Chen, WX
    Shen, H
    Webb, A
    KuoLee, R
    [J]. MICROBIAL PATHOGENESIS, 2003, 34 (05) : 239 - 248
  • [7] Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS
    Conlan, JW
    KuoLee, R
    Shen, H
    Webb, A
    [J]. MICROBIAL PATHOGENESIS, 2002, 32 (03) : 127 - 134
  • [8] Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen
    Conlan, JW
    Shen, H
    Webb, A
    Perry, MB
    [J]. VACCINE, 2002, 20 (29-30) : 3465 - 3471
  • [9] Tularemia as a biological weapon - Medical and public health management
    Dennis, DT
    Inglesby, TV
    Henderson, DA
    Bartlett, JG
    Ascher, MS
    Eitzen, E
    Fine, AD
    Friedlander, AM
    Hauer, J
    Layton, M
    Lillibridge, SR
    McDade, JE
    Osterholm, MT
    O'Toole, T
    Parker, G
    Perl, TM
    Russell, PK
    Tonat, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21): : 2763 - 2773
  • [10] EVANS TJ, 1993, J IMMUNOL, V150, P5033